| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexbrompheniramine. | Experimental, Illicit |
| 3,4-Methylenedioxyamphetamine | 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexbrompheniramine. | Experimental, Illicit |
| 3,4-Methylenedioxymethamphetamine | 3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Dexbrompheniramine. | Experimental, Illicit |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexbrompheniramine. | Experimental, Illicit |
| 7-Nitroindazole | The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dexbrompheniramine. | Experimental |
| Acepromazine | The risk or severity of adverse effects can be increased when Acepromazine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Aceprometazine | The risk or severity of adverse effects can be increased when Aceprometazine is combined with Dexbrompheniramine. | Approved |
| Adipiplon | The risk or severity of adverse effects can be increased when adipiplon is combined with Dexbrompheniramine. | Investigational |
| Agomelatine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Dexbrompheniramine. | Approved, Investigational |
| Alfaxalone | The risk or severity of adverse effects can be increased when Alfaxalone is combined with Dexbrompheniramine. | Vet Approved |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Dexbrompheniramine. | Approved, Illicit |
| Allopregnanolone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sage 547. | Investigational |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dexbrompheniramine. | Experimental, Illicit |
| Alprazolam | The risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine. | Approved, Illicit, Investigational |
| Amisulpride | The risk or severity of adverse effects can be increased when Amisulpride is combined with Dexbrompheniramine. | Approved, Investigational |
| Amitriptyline | The risk or severity of adverse effects can be increased when Amitriptyline is combined with Dexbrompheniramine. | Approved |
| Amobarbital | The risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine. | Approved, Illicit |
| Amoxapine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine. | Approved |
| Amperozide | The risk or severity of adverse effects can be increased when Amperozide is combined with Dexbrompheniramine. | Experimental |
| Amphetamine | Amphetamine may decrease the sedative activities of Dexbrompheniramine. | Approved, Illicit |
| Aripiprazole | The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine. | Approved, Investigational |
| Articaine | The risk or severity of adverse effects can be increased when Articaine is combined with Dexbrompheniramine. | Approved |
| Asenapine | The risk or severity of adverse effects can be increased when Asenapine is combined with Dexbrompheniramine. | Approved |
| Azelastine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | Approved |
| Azelastine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Azelastine. | Approved |
| Baclofen | The risk or severity of adverse effects can be increased when Baclofen is combined with Dexbrompheniramine. | Approved |
| Barbital | The risk or severity of adverse effects can be increased when Barbital is combined with Dexbrompheniramine. | Illicit |
| Benperidol | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benperidol. | Investigational |
| Benzocaine | The risk or severity of adverse effects can be increased when Benzocaine is combined with Dexbrompheniramine. | Approved |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Dexbrompheniramine. | Approved, Illicit |
| Benzyl alcohol | The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dexbrompheniramine. | Approved |
| Benzylpenicilloyl Polylysine | Dexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. | Approved |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexbrompheniramine. | Approved |
| Brexpiprazole | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brimonidine. | Approved |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved |
| Bromazepam | The risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine. | Approved, Illicit |
| Brompheniramine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine. | Approved |
| Brotizolam | The risk or severity of adverse effects can be increased when Brotizolam is combined with Dexbrompheniramine. | Approved, Withdrawn |
| Bupivacaine | The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexbrompheniramine. | Approved, Investigational |
| Buprenorphine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Buspirone | The risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine. | Approved, Investigational |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine. | Approved, Illicit |
| Butalbital | The risk or severity of adverse effects can be increased when Butalbital is combined with Dexbrompheniramine. | Approved, Illicit |
| Butethal | The risk or severity of adverse effects can be increased when Butethal is combined with Dexbrompheniramine. | Approved, Illicit |
| Butorphanol | The risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine. | Approved, Illicit, Vet Approved |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine. | Approved, Investigational |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbinoxamine. | Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with Dexbrompheniramine. | Illicit, Vet Approved |
| Carisoprodol | The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine. | Approved |
| Cetirizine | The risk or severity of adverse effects can be increased when Cetirizine is combined with Dexbrompheniramine. | Approved |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dexbrompheniramine. | Approved, Illicit, Vet Approved |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexbrompheniramine. | Approved, Illicit |
| Chlormezanone | The risk or severity of adverse effects can be increased when Chlormezanone is combined with Dexbrompheniramine. | Approved, Withdrawn |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dexbrompheniramine. | Approved |
| Chlorphenamine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenamine. | Approved |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Dexbrompheniramine. | Illicit, Withdrawn |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Chlorprothixene | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexbrompheniramine. | Approved, Withdrawn |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine. | Approved |
| Cinchocaine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Citalopram | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram. | Approved |
| Clemastine | The risk or severity of adverse effects can be increased when Clemastine is combined with Dexbrompheniramine. | Approved |
| Clidinium | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium. | Approved |
| Clobazam | The risk or severity of adverse effects can be increased when Clobazam is combined with Dexbrompheniramine. | Approved, Illicit |
| Clomipramine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomipramine. | Approved, Vet Approved |
| Clonazepam | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonazepam. | Approved, Illicit |
| Clonidine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine. | Approved |
| Clorazepate | The risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine. | Approved, Illicit |
| Clozapine | The risk or severity of adverse effects can be increased when Clozapine is combined with Dexbrompheniramine. | Approved |
| Cocaine | The risk or severity of adverse effects can be increased when Cocaine is combined with Dexbrompheniramine. | Approved, Illicit |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine. | Approved, Illicit |
| Cyclizine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclizine. | Approved |
| Cyclobenzaprine | The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine. | Approved |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine. | Approved |
| Dantrolene | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene. | Approved |
| Dapiprazole | The risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexbrompheniramine. | Approved |
| Dapoxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine. | Investigational |
| Deramciclane | The risk or severity of adverse effects can be increased when deramciclane is combined with Dexbrompheniramine. | Investigational |
| Desflurane | The risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine. | Approved |
| Desipramine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine. | Approved |
| Desloratadine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine. | Approved, Investigational |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Dexbrompheniramine. | Approved, Illicit |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Dexbrompheniramine. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dexbrompheniramine. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Dexbrompheniramine. | Approved |
| Diazepam | The risk or severity of adverse effects can be increased when Diazepam is combined with Dexbrompheniramine. | Approved, Illicit, Vet Approved |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Dexbrompheniramine. | Approved, Illicit |
| Difenoxin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Difenoxin. | Approved, Illicit |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine. | Approved, Illicit |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dexbrompheniramine. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dexbrompheniramine. | Experimental, Illicit |
| Dimenhydrinate | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimenhydrinate. | Approved |
| Diphenhydramine | The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine. | Approved, Illicit |
| Doxepin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin. | Approved |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved, Vet Approved |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved, Illicit |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved, Vet Approved |
| Drotebanol | The risk or severity of adverse effects can be increased when Drotebanol is combined with Dexbrompheniramine. | Experimental, Illicit |
| Duloxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine. | Approved |
| Dyclonine | The risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine. | Approved |
| Ecgonine | The risk or severity of adverse effects can be increased when Ecgonine is combined with Dexbrompheniramine. | Experimental, Illicit |
| Ecopipam | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ecopipam. | Investigational |
| Efavirenz | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz. | Approved, Investigational |
| Eltanolone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pregnanolone. | Investigational |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Entacapone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone. | Approved, Investigational |
| Escitalopram | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram. | Approved, Investigational |
| Estazolam | The risk or severity of adverse effects can be increased when Estazolam is combined with Dexbrompheniramine. | Approved, Illicit |
| Eszopiclone | The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine. | Approved |
| Ethanol | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | Approved |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine. | Approved, Illicit, Withdrawn |
| Ethosuximide | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide. | Approved |
| Ethotoin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin. | Approved |
| Ethyl carbamate | The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dexbrompheniramine. | Withdrawn |
| Ethyl loflazepate | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dexbrompheniramine. | Approved, Illicit |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dexbrompheniramine. | Approved, Illicit |
| Etidocaine | The risk or severity of adverse effects can be increased when Etidocaine is combined with Dexbrompheniramine. | Approved |
| Etifoxine | The risk or severity of adverse effects can be increased when Etifoxine is combined with Dexbrompheniramine. | Withdrawn |
| Etizolam | The risk or severity of adverse effects can be increased when Etizolam is combined with Dexbrompheniramine. | Approved |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Dexbrompheniramine. | Approved |
| Etoperidone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etoperidone. | Approved |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Dexbrompheniramine. | Illicit, Vet Approved |
| Ezogabine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ezogabine. | Approved |
| Felbamate | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate. | Approved |
| Fencamfamine | The risk or severity of adverse effects can be increased when Fencamfamine is combined with Dexbrompheniramine. | Approved, Illicit, Withdrawn |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine. | Approved, Illicit, Investigational, Vet Approved |
| Fexofenadine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fexofenadine. | Approved |
| Flibanserin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin. | Approved |
| Fludiazepam | The risk or severity of adverse effects can be increased when Fludiazepam is combined with Dexbrompheniramine. | Approved, Illicit |
| Flunarizine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine. | Approved |
| Flunitrazepam | The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dexbrompheniramine. | Approved, Illicit |
| Fluoxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluoxetine. | Approved, Vet Approved |
| Flupentixol | The risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine. | Approved, Withdrawn |
| Fluphenazine | The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine. | Approved |
| Flurazepam | The risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine. | Approved, Illicit |
| Fluspirilene | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Dexbrompheniramine. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone Propionate. | Approved |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dexbrompheniramine. | Approved, Investigational |
| Fosphenytoin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin. | Approved |
| Fospropofol | The risk or severity of adverse effects can be increased when Fospropofol is combined with Dexbrompheniramine. | Approved, Illicit |
| Gabapentin | The risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine. | Approved, Investigational |
| Gabapentin Enacarbil | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with gabapentin enacarbil. | Approved |
| Gamma Hydroxybutyric Acid | The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dexbrompheniramine. | Approved, Illicit |
| Gepirone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gepirone. | Investigational |
| Glutethimide | The risk or severity of adverse effects can be increased when Glutethimide is combined with Dexbrompheniramine. | Approved, Illicit |
| Guanfacine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine. | Approved, Investigational |
| Halazepam | The risk or severity of adverse effects can be increased when Halazepam is combined with Dexbrompheniramine. | Approved, Illicit, Withdrawn |
| Haloperidol | The risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Halothane is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Heroin | The risk or severity of adverse effects can be increased when Heroin is combined with Dexbrompheniramine. | Approved, Illicit |
| Hexobarbital | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dexbrompheniramine. | Approved |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine. | Approved, Investigational |
| Hydrocodone | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | Approved, Illicit |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine. | Approved, Illicit |
| Hydroxyamphetamine | Hydroxyamphetamine hydrobromide may decrease the sedative activities of Dexbrompheniramine. | Approved |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved |
| Iloperidone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iloperidone. | Approved |
| Imipramine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine. | Approved |
| Indalpine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine. | Investigational, Withdrawn |
| Isoflurane | The risk or severity of adverse effects can be increased when Isoflurane is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Ketamine | The risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Ketazolam | The risk or severity of adverse effects can be increased when Ketazolam is combined with Dexbrompheniramine. | Approved |
| Ketobemidone | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Dexbrompheniramine. | Approved |
| Lamotrigine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine. | Approved, Investigational |
| Levetiracetam | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam. | Approved, Investigational |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dexbrompheniramine. | Approved |
| Levocabastine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocabastine. | Approved |
| Levocetirizine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocetirizine. | Approved |
| Levodopa | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa. | Approved |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dexbrompheniramine. | Approved |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine. | Approved |
| Lidocaine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Dexbrompheniramine. | Approved, Investigational |
| Lithium | The risk or severity of adverse effects can be increased when Lithium is combined with Dexbrompheniramine. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Lofentanil is combined with Dexbrompheniramine. | Illicit |
| Loratadine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loratadine. | Approved |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine. | Approved |
| Loxapine | The risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine. | Approved |
| Lurasidone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine. | Approved |
| Magnesium Sulfate | Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved, Vet Approved |
| Maprotiline | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline. | Approved |
| Meclizine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meclizine. | Approved |
| Melatonin | The risk or severity of adverse effects can be increased when Melatonin is combined with Dexbrompheniramine. | Approved, Nutraceutical, Vet Approved |
| Melperone | The risk or severity of adverse effects can be increased when Melperone is combined with Dexbrompheniramine. | Approved |
| Mephedrone | Mephedrone may decrease the sedative activities of Dexbrompheniramine. | Investigational |
| Mephentermine | Mephentermine may decrease the sedative activities of Dexbrompheniramine. | Approved |
| Mepivacaine | The risk or severity of adverse effects can be increased when Mepivacaine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Meprobamate | The risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine. | Approved, Illicit |
| Mesoridazine | The risk or severity of adverse effects can be increased when Mesoridazine is combined with Dexbrompheniramine. | Approved |
| Metaxalone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone. | Approved |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dexbrompheniramine. | Approved, Illicit |
| Methamphetamine | Methamphetamine may decrease the sedative activities of Dexbrompheniramine. | Approved, Illicit |
| Methapyrilene | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Dexbrompheniramine. | Withdrawn |
| Methaqualone | The risk or severity of adverse effects can be increased when Methaqualone is combined with Dexbrompheniramine. | Illicit, Withdrawn |
| Methocarbamol | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol. | Approved, Vet Approved |
| Methohexital | The risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine. | Approved |
| Methotrimeprazine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | Approved |
| Methoxyflurane | The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Methsuximide | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide. | Approved |
| Methylecgonine | The risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Dexbrompheniramine. | Experimental |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dexbrompheniramine. | Approved |
| Metyrosine | Dexbrompheniramine may increase the sedative activities of Metyrosine. | Approved |
| Midazolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine. | Approved, Illicit |
| Milnacipran | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran. | Approved |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved, Investigational |
| Mirtazapine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. | Approved |
| MMDA | MMDA may decrease the sedative activities of Dexbrompheniramine. | Experimental, Illicit |
| Molindone | The risk or severity of adverse effects can be increased when Molindone is combined with Dexbrompheniramine. | Approved |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine. | Approved, Investigational |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved, Investigational |
| Nalbuphine | The risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine. | Approved |
| Nefazodone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefazodone. | Approved, Withdrawn |
| Nitrazepam | The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine. | Approved |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Norflurane | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 1,1,1,2 Tetrafluoroethane. | Investigational |
| Normethadone | The risk or severity of adverse effects can be increased when Normethadone is combined with Dexbrompheniramine. | Approved, Illicit |
| Nortriptyline | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline. | Approved |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine. | Approved, Investigational |
| Olopatadine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine. | Approved |
| Ondansetron | The risk or severity of adverse effects can be increased when Ondansetron is combined with Dexbrompheniramine. | Approved |
| Opium | The risk or severity of adverse effects can be increased when Opium is combined with Dexbrompheniramine. | Approved, Illicit |
| Orphenadrine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. | Approved |
| Osanetant | The risk or severity of adverse effects can be increased when Osanetant is combined with Dexbrompheniramine. | Investigational |
| Oxazepam | The risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine. | Approved |
| Oxethazaine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxetacaine. | Investigational |
| Oxprenolol | The risk or severity of adverse effects can be increased when Oxprenolol is combined with Dexbrompheniramine. | Approved |
| Oxybuprocaine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dexbrompheniramine. | Approved |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine. | Approved, Investigational, Vet Approved |
| Paliperidone | The risk or severity of adverse effects can be increased when Paliperidone is combined with Dexbrompheniramine. | Approved |
| Paraldehyde | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | Approved |
| Paroxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine. | Approved, Investigational |
| Pentazocine | The risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Pentobarbital | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved |
| Perazine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perazine. | Investigational |
| Perospirone | The risk or severity of adverse effects can be increased when Perospirone is combined with Dexbrompheniramine. | Approved |
| Perphenazine | The risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine. | Approved |
| Phenobarbital | The risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine. | Approved |
| Phentermine | Phentermine may decrease the sedative activities of Dexbrompheniramine. | Approved, Illicit |
| Phenytoin | The risk or severity of adverse effects can be increased when Phenytoin is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Pimozide | The risk or severity of adverse effects can be increased when Pimozide is combined with Dexbrompheniramine. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Pipamperone is combined with Dexbrompheniramine. | Approved |
| Pipotiazine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine. | Approved |
| Piritramide | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piritramide. | Investigational |
| Pomalidomide | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide. | Approved |
| Pramipexole | Dexbrompheniramine may increase the sedative activities of Pramipexole. | Approved, Investigational |
| Pramocaine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Dexbrompheniramine. | Approved |
| Prazepam | The risk or severity of adverse effects can be increased when Prazepam is combined with Dexbrompheniramine. | Approved, Illicit |
| Pregabalin | The risk or severity of adverse effects can be increased when Pregabalin is combined with Dexbrompheniramine. | Approved, Illicit, Investigational |
| Prilocaine | The risk or severity of adverse effects can be increased when Prilocaine is combined with Dexbrompheniramine. | Approved |
| Primidone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Primidone. | Approved, Vet Approved |
| Procaine | The risk or severity of adverse effects can be increased when Procaine is combined with Dexbrompheniramine. | Approved, Investigational, Vet Approved |
| Prochlorperazine | The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Promethazine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine. | Approved |
| Proparacaine | The risk or severity of adverse effects can be increased when Proparacaine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Propofol | The risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine. | Approved, Investigational, Vet Approved |
| Propoxycaine | The risk or severity of adverse effects can be increased when Propoxycaine is combined with Dexbrompheniramine. | Approved |
| Protriptyline | The risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine. | Approved |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Dexbrompheniramine. | Approved |
| Quazepam | The risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine. | Approved, Illicit |
| Quetiapine | The risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine. | Approved |
| Raclopride | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Raclopride. | Investigational |
| Ramelteon | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon. | Approved, Investigational |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine. | Approved |
| Remoxipride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dexbrompheniramine. | Approved, Withdrawn |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine. | Approved |
| Risperidone | The risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine. | Approved, Investigational |
| Ritanserin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ritanserin. | Investigational |
| Ritobegron | Ritobegron may decrease the sedative activities of Dexbrompheniramine. | Investigational |
| Ropinirole | Dexbrompheniramine may increase the sedative activities of Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexbrompheniramine. | Approved |
| Rotigotine | Dexbrompheniramine may increase the sedative activities of Rotigotine. | Approved |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dexbrompheniramine. | Approved |
| Scopolamine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine. | Approved |
| Secobarbital | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Sepranolone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Uc1010. | Investigational |
| Sertindole | The risk or severity of adverse effects can be increased when Sertindole is combined with Dexbrompheniramine. | Approved, Withdrawn |
| Sertraline | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Sodium oxybate | Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved |
| Stiripentol | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Stiripentol. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine. | Approved, Investigational |
| Sulpiride | The risk or severity of adverse effects can be increased when Sulpiride is combined with Dexbrompheniramine. | Approved |
| Suvorexant | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | Approved |
| Tandospirone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tandospirone. | Investigational |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. | Approved |
| Tasimelteon | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tasimelteon. | Approved |
| Temazepam | The risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine. | Approved |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrabenazine. | Approved |
| Tetracaine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Tetrodotoxin | The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dexbrompheniramine. | Investigational |
| Thalidomide | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | Approved, Investigational, Withdrawn |
| Thiamylal | The risk or severity of adverse effects can be increased when Thiamylal is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Thiopental | The risk or severity of adverse effects can be increased when Thiopental is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Thioridazine | The risk or severity of adverse effects can be increased when Thioridazine is combined with Dexbrompheniramine. | Withdrawn |
| Thiothixene | The risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine. | Approved |
| Tiagabine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine. | Approved |
| Tiapride | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiapride. | Approved, Investigational |
| Tizanidine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine. | Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine. | Approved, Withdrawn |
| Topiramate | The risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine. | Approved |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine. | Approved, Investigational |
| Trans-2-Phenylcyclopropylamine | The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dexbrompheniramine. | Experimental |
| Tranylcypromine | The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dexbrompheniramine. | Approved |
| Trazodone | The risk or severity of adverse effects can be increased when Trazodone is combined with Dexbrompheniramine. | Approved, Investigational |
| Triazolam | The risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine. | Approved |
| Trifluoperazine | The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine. | Approved |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexbrompheniramine. | Approved, Vet Approved |
| Trimipramine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine. | Approved |
| Triprolidine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine. | Approved |
| Valproic Acid | The risk or severity of adverse effects can be increased when Valproic Acid is combined with Dexbrompheniramine. | Approved, Investigational |
| Venlafaxine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Venlafaxine. | Approved |
| Vigabatrin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin. | Approved |
| Vortioxetine | The risk or severity of adverse effects can be increased when Vortioxetine is combined with Dexbrompheniramine. | Approved |
| Zaleplon | The risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine. | Approved, Illicit, Investigational |
| Ziconotide | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide. | Approved |
| Zimelidine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine. | Withdrawn |
| Ziprasidone | The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine. | Approved |
| Zolpidem | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | Approved |
| Zonisamide | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide. | Approved, Investigational |
| Zopiclone | The risk or severity of adverse effects can be increased when Zopiclone is combined with Dexbrompheniramine. | Approved |
| Zotepine | The risk or severity of adverse effects can be increased when Zotepine is combined with Dexbrompheniramine. | Approved |
| Zuclopenthixol | The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexbrompheniramine. | Approved, Investigational |
